The nursing seat has a built-in ventilator that delivers oxygen to the lungs and helps prevent pneumonia, according to a study published in the journal Clinical Oncology.
The device was created by a company called BioNano, which has raised more than $1.5 billion in venture funding to develop the device.
BioNanos founder and CEO Mark P. Dutkiewicz is a former clinical oncologist at Stanford Medical Center and a former president of the American Academy of Oncologists.
He co-founded the company in 2012.
“I am the father of a daughter, so I feel like it’s my responsibility to do everything I can to protect her,” Dutchiewicz said.
In a statement to Recode, BioNans CEO Andrew Tovar said the company “fully supports” the findings of the study.
He added, “The company has never marketed any type of oxygen device, including the BioNanos BioNova, as a respiratory therapy device.”
The study also found that the ventilators did not provide enough oxygen to patients with COVID-19 and that patients were able to keep breathing after they were removed from the device for two days.
A person can breathe normally for three days after their ventilating device is removed.
The company said it’s working with patients to determine if other devices could help with the COVID process.
BioCodes could help treat other respiratory diseases that can cause breathing problems, including pneumonia, COPD, and asthma.
“We believe that these results will provide important evidence for potential new therapies,” P.D.T. said in a statement.
“These are important clinical trials that could potentially lead to more treatments for COVID and respiratory disease.”
The device’s creators are working with several other medical device companies to see if there are any other potential treatments for the respiratory problems that are associated with COIDS, including a nasal spray that can be used for asthma, the statement said.